Post by @trav.health

You are NOT allowed to comment until you read this caption 🔫 The comments I get every time: ‘Reta isn’t a GLP-1.’ It’s a triple agonist. One of the three receptors it activates IS the GLP-1 receptor, through the exact same signaling pathway as semaglutide. Adding GIP and glucagon activity doesn’t remove the GLP-1 activity. It stacks on top of it. ‘It slows emptying but not enough to cause SIBO.’ Gastric emptying isn’t the mechanism that causes SIBO. The migrating motor complex is. GLP-1 receptor activation suppresses the MMC, the wave that sweeps bacteria out of the small intestine between meals. Human manometry studies show this directly. ‘Dose matters.’ Correct. The motility effect is dose-dependent and peaks during titration. So if you’re climbing doses and the bloating shows up, that’s not a coincidence and it’s not nothing. Dose dependence doesn’t make the risk go away. It tells you when to watch for it. ‘The benefits outweigh the cons.’ Maybe they do, for you. That’s a real calculation and I’m not telling you to stop. But a risk-benefit decision is only as good as the information in it. If SIBO isn’t on the cons side of your math, you’re not weighing benefits against cons. You’re weighing benefits against the cons you happen to know about.